Rapid-Throughput Skeletal Phenotyping of 100 Knockout Mice Identifies 9 New Genes That Determine Bone Strength

PLoS Genetics

Volumn 8, Issue 8, 2012, Pages

  Bassett, J H Duncan ^a   Gogakos, Apostolos ^a   White, Jacqueline K ^b   Evans, Holly ^c   Jacques, Richard M ^d   van der Spek, Anne H ^a   Ramirez Solis, Ramiro ^b   Ryder, Edward ^b   Sunter, David ^b   Boyde, Alan ^e   Campbell, Michael J ^d   Croucher, Peter I ^c,f   Williams, Graham R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CELL ADHESION MOLECULE; OSTEONECTIN; RIBOSEPHOSPHATE PYROPHOSPHOKINASE;

ACCURACY; ADDITIONAL SEX COMBS LIKE 1 GENE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BOBBY SOX HOMOLOG GENE; BONE MASS; BONE STRENGTH; BONE STRUCTURE; CELL ADHESION MOLECULE 1 GENE; CONTROLLED STUDY; FAMILY WITH SEQUENCE SIMILARITY 73 MEMBER B GENE; FEMALE; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; HIGH THROUGHPUT SEQUENCING; KNOCKOUT MOUSE; MICRO-COMPUTED TOMOGRAPHY; MICRORADIOGRAPHY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEONECTIN GENE; PHENOTYPE; PHOSPHORIBOSYL PYROPHOSPHATE SYNTHETASE ASSOCIATED PROTEIN 2 GENE; PREDICTION; SENSITIVITY AND SPECIFICITY; SET DOMAIN BIFURCATED 1 GENE; SOLUTE CARRIER FAMILY 38 MEMBER 10 GENE; SPINSTER HOMOLOG 2 GENE; TRIPARTITE MOTIF CONTAINING PROTEIN 45 GENE; VALIDATION PROCESS;

ANIMALS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; CHROMOSOME MAPPING; GENE DELETION; HIGH-THROUGHPUT SCREENING ASSAYS; MICE; MICE, KNOCKOUT; MICRORADIOGRAPHY; ORGAN SPECIFICITY; OSTEOPOROSIS; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TENSILE STRENGTH;

MUS;

EID: 84866161266     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1002858     Document Type: Article

References (87)

1. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, et al. (1999) Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341: 879-884.
2. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, et al. (1997) Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387: 903-908.
3. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, et al. (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355: 467-477.
4. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, et al. (1996) Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 384: 455-458.
5. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, et al. (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68: 577-589.
6. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, et al. (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276: 404-407.
7. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, et al. (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107: 513-523.
8. Collins FS, Rossant J, Wurst W, (2007) A mouse for all reasons. Cell 128: 9-13.
9. Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, et al. (2011) A conditional knockout resource for the genome-wide study of mouse gene function. Nature 474: 337-342.
10. Johnell O, Kanis JA, (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17: 1726-1733.
11. Ralston SH, Uitterlinden AG, (2010) Genetics of osteoporosis. Endocr Rev 31: 629-662.
12. Rivadeneira F, Styrkarsdottir U, Estrada K, Halldorsson BV, Hsu YH, et al. (2009) Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 41: 1199-1206.
13. Cirulli ET, Goldstein DB, (2010) Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 11: 415-425.
14. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, et al. (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85: 4118-4124.
15. Mackey DC, Black DM, Bauer DC, McCloskey EV, Eastell R, et al. (2011) Effects of antiresorptive treatment on non-vertebral fracture outcomes. J Bone Miner Res 26: 2411-2418.
16. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, et al. (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346: 1513-1521.
17. Rachner TD, Khosla S, Hofbauer LC, (2011) Osteoporosis: now and the future. Lancet 377: 1276-1287.
18. Brown SD, Chambon P, de Angelis MH, (2005) EMPReSS: standardized phenotype screens for functional annotation of the mouse genome. Nat Genet 37: 1155.
19. Justice MJ, (2008) Removing the cloak of invisibility: phenotyping the mouse. Dis Model Mech 1: 109-112.
20. Karp NA, Baker LA, Gerdin AK, Adams NC, Ramirez-Solis R, et al. (2010) Optimising experimental design for high-throughput phenotyping in mice: a case study. Mamm Genome 21: 467-476.
21. Hardisty-Hughes RE, Parker A, Brown SD, (2010) A hearing and vestibular phenotyping pipeline to identify mouse mutants with hearing impairment. Nat Protoc 5: 177-190.
22. Boskey AL, Moore DJ, Amling M, Canalis E, Delany AM, (2003) Infrared analysis of the mineral and matrix in bones of osteonectin-null mice and their wildtype controls. J Bone Miner Res 18: 1005-1011.
23. Delany AM, Amling M, Priemel M, Howe C, Baron R, et al. (2000) Osteopenia and decreased bone formation in osteonectin-deficient mice. J Clin Invest 105: 915-923.
24. Everitt B, editor. An R and S-PLUS Companion to Multivariate Analysis. London: Springer.
25. Mitchell AFS, Krzanowski WJ, (1985) The Mahalanobis distance and elliptic distributions. Biometrika 72: 464-467.
26. Rousseeuw PJ, (1985) Multivariate estimation with high breakdown point;. W. Grossmann GP, I. Vinceze, and W. Wertz, Eds., editor The Netherlands: Reidel. pp. 283-297.
27. Rousseeuw PJ, Van Zomeren BC, (1990) Unmasking Multivariate Outliers and Leverage Points. Journal of the American Statistical Association 85: 633-639.
28. Ammann P, Rizzoli R, (2003) Bone strength and its determinants. Osteoporos Int 14 Suppl 3: S13-18.
29. Boyle WJ, Simonet WS, Lacey DL, (2003) Osteoclast differentiation and activation. Nature 423: 337-342.
30. Harada S, Rodan GA, (2003) Control of osteoblast function and regulation of bone mass. Nature 423: 349-355.
31. Dickenson RP, Hutton WC, Stott JR, (1981) The mechanical properties of bone in osteoporosis. J Bone Joint Surg Br 63-B: 233-238.
32. Marchler-Bauer A, Anderson JB, Chitsaz F, Derbyshire MK, DeWeese-Scott C, et al. (2009) CDD: specific functional annotation with the Conserved Domain Database. Nucleic Acids Res 37: D205-210.
33. Dailey L, Basilico C, (2001) Coevolution of HMG domains and homeodomains and the generation of transcriptional regulation by Sox/POU complexes. J Cell Physiol 186: 315-328.
34. Laudet V, Stehelin D, Clevers H, (1993) Ancestry and diversity of the HMG box superfamily. Nucleic Acids Res 21: 2493-2501.
35. Love JJ, Li X, Case DA, Giese K, Grosschedl R, et al. (1995) Structural basis for DNA bending by the architectural transcription factor LEF-1. Nature 376: 791-795.
36. Pohler JR, Norman DG, Bramham J, Bianchi ME, Lilley DM, (1998) HMG box proteins bind to four-way DNA junctions in their open conformation. EMBO J 17: 817-826.
37. Bernard P, Tang P, Liu S, Dewing P, Harley VR, et al. (2003) Dimerization of SOX9 is required for chondrogenesis, but not for sex determination. Hum Mol Genet 12: 1755-1765.
38. Mundlos S, Olsen BR, (1997) Heritable diseases of the skeleton. Part I: Molecular insights into skeletal development-transcription factors and signaling pathways. FASEB J 11: 125-132.
39. MacDonald BT, Tamai K, He X, (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26.
40. Balemans W, Van Hul W, (2007) The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. Endocrinology 148: 2622-2629.
41. Baron R, Rawadi G, (2007) Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep 5: 73-80.
42. Chan A, van Bezooijen RL, Lowik CW, (2007) A new paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists. Curr Opin Investig Drugs 8: 293-298.
43. Luyten FP, Tylzanowski P, Lories RJ, (2009) Wnt signaling and osteoarthritis. Bone 44: 522-527.
44. Giangreco A, Jensen KB, Takai Y, Miyoshi J, Watt FM, (2009) Necl2 regulates epidermal adhesion and wound repair. Development 136: 3505-3514.
45. Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, et al. (2001) TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 27: 427-430.
46. Biederer T, Sara Y, Mozhayeva M, Atasoy D, Liu X, et al. (2002) SynCAM, a synaptic adhesion molecule that drives synapse assembly. Science 297: 1525-1531.
47. Takayanagi Y, Fujita E, Yu Z, Yamagata T, Momoi MY, et al. (2010) Impairment of social and emotional behaviors in Cadm1-knockout mice. Biochem Biophys Res Commun 396: 703-708.
48. Giangreco A, Hoste E, Takai Y, Rosewell I, Watt FM, (2012) Epidermal Cadm1 expression promotes autoimmune alopecia via enhanced T cell adhesion and cytotoxicity. J Immunol 188: 1514-1522.
49. Ito A, Hagiyama M, Oonuma J, (2008) Nerve-mast cell and smooth muscle-mast cell interaction mediated by cell adhesion molecule-1, CADM1. J Smooth Muscle Res 44: 83-93.
50. Fujita E, Kouroku Y, Ozeki S, Tanabe Y, Toyama Y, et al. (2006) Oligo-astheno-teratozoospermia in mice lacking RA175/TSLC1/SynCAM/IGSF4A, a cell adhesion molecule in the immunoglobulin superfamily. Mol Cell Biol 26: 718-726.
51. Rauch F, Glorieux FH, (2004) Osteogenesis imperfecta. Lancet 363: 1377-1385.
52. Tatibana M, Kita K, Taira M, Ishijima S, Sonoda T, et al. (1995) Mammalian phosphoribosyl-pyrophosphate synthetase. Adv Enzyme Regul 35: 229-249.
53. Katashima R, Iwahana H, Fujimura M, Yamaoka T, Itakura M, (1998) Assignment of the human phosphoribosylpyrophosphate synthetase-associated protein 41 gene (PRPSAP2) to 17p11.2-p12. Genomics 54: 180-181.
54. Both J, Wu T, Bras J, Schaap GR, Baas F, et al. (2012) Identification of novel candidate oncogenes in chromosome region 17p11.2-p12 in human osteosarcoma. PLoS One 7: e30907.
55. Sundberg BE, Waag E, Jacobsson JA, Stephansson O, Rumaks J, et al. (2008) The evolutionary history and tissue mapping of amino acid transporters belonging to solute carrier families SLC32, SLC36, and SLC38. J Mol Neurosci 35: 179-193.
56. Franchi-Gazzola R, Dall'Asta V, Sala R, Visigalli R, Bevilacqua E, et al. (2006) The role of the neutral amino acid transporter SNAT2 in cell volume regulation. Acta Physiol (Oxf) 187: 273-283.
57. Kronenberg HM, (2003) Developmental regulation of the growth plate. Nature 423: 332-336.
58. Hiraoka S, Furuichi T, Nishimura G, Shibata S, Yanagishita M, et al. (2007) Nucleotide-sugar transporter SLC35D1 is critical to chondroitin sulfate synthesis in cartilage and skeletal development in mouse and human. Nat Med 13: 1363-1367.
59. Superti-Furga A, Hastbacka J, Rossi A, van der Harten JJ, Wilcox WR, et al. (1996) A family of chondrodysplasias caused by mutations in the diastrophic dysplasia sulfate transporter gene and associated with impaired sulfation of proteoglycans. Ann N Y Acad Sci 785: 195-201.
60. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, et al. (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23: 860-869.
61. Akhter MP, Wells DJ, Short SJ, Cullen DM, Johnson ML, et al. (2004) Bone biomechanical properties in LRP5 mutant mice. Bone 35: 162-169.
62. Lee SW, Cho YS, Na JM, Park UH, Kang M, et al. (2010) ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem 285: 18-29.
63. Fisher CL, Lee I, Bloyer S, Bozza S, Chevalier J, et al. (2010) Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. Dev Biol 337: 9-15.
64. Wellik DM, (2007) Hox patterning of the vertebrate axial skeleton. Dev Dyn 236: 2454-2463.
65. Williams JA, Kondo N, Okabe T, Takeshita N, Pilchak DM, et al. (2009) Retinoic acid receptors are required for skeletal growth, matrix homeostasis and growth plate function in postnatal mouse. Dev Biol 328: 315-327.
66. Hoischen A, van Bon BW, Rodriguez-Santiago B, Gilissen C, Vissers LE, et al. (2011) De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nat Genet 43: 729-731.
67. Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ 3rd, (2002) SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev 16: 919-932.
68. Yang L, Xia L, Wu DY, Wang H, Chansky HA, et al. (2002) Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor. Oncogene 21: 148-152.
69. Nifuji A, Ideno H, Ohyama Y, Takanabe R, Araki R, et al. (2010) Nemo-like kinase (NLK) expression in osteoblastic cells and suppression of osteoblastic differentiation. Exp Cell Res 316: 1127-1136.
70. Takada I, Mihara M, Suzawa M, Ohtake F, Kobayashi S, et al. (2007) A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol 9: 1273-1285.
71. Hisano Y, Kobayashi N, Kawahara A, Yamaguchi A, Nishi T, (2011) The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720. J Biol Chem 286: 1758-1766.
72. Ishii M, Egen JG, Klauschen F, Meier-Schellersheim M, Saeki Y, et al. (2009) Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458: 524-528.
73. Ishii T, Shimazu Y, Nishiyama I, Kikuta J, Ishii M, (2011) The role of sphingosine 1-phosphate in migration of osteoclast precursors; an application of intravital two-photon microscopy. Mol Cells 31: 399-403.
74. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ, (2008) Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A 105: 20764-20769.
75. Ryu J, Kim HJ, Chang EJ, Huang H, Banno Y, et al. (2006) Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J 25: 5840-5851.
76. Chu Y, Yang X, (2011) SUMO E3 ligase activity of TRIM proteins. Oncogene 30: 1108-1116.
77. Napolitano LM, Jaffray EG, Hay RT, Meroni G, (2011) Functional interactions between ubiquitin E2 enzymes and TRIM proteins. Biochem J 434: 309-319.
78. Ozato K, Shin DM, Chang TH, Morse HC 3rd, (2008) TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 8: 849-860.
79. Wang Y, Li Y, Qi X, Yuan W, Ai J, et al. (2004) TRIM45, a novel human RBCC/TRIM protein, inhibits transcriptional activities of ElK-1 and AP-1. Biochem Biophys Res Commun 323: 9-16.
80. Komori T, (2006) Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 99: 1233-1239.
81. Wagner EF, (2010) Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun). Ann Rheum Dis 69 Suppl 1: i86-88.
82. Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, et al. (2008) Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 371: 1505-1512.
83. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, et al. (2008) Multiple genetic loci for bone mineral density and fractures. N Engl J Med 358: 2355-2365.
84. Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, et al. (2012) Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 44: 491-501.
85. Bassett JH, Boyde A, Howell PG, Bassett RH, Galliford TM, et al. (2010) Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. Proc Natl Acad Sci U S A 107: 7604-7609.
86. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595-610.
87. Venables WN, Ripley BD (2002) Modern Applied Statistics with S New York, NY, USA: Springer.